Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells

Tumor-targeted radiotherapy can synergize with CTLA-4 blockade to induce T cell–mediated rejection of tumors refractory to CTLA-4 blockade alone. The resultant T-cell repertoire has unique characteristics that suggest a diverse T-cell response is critical for tumor rejection. Immune checkpoint inhibitors activate T cells to reject tumors. Unique tumor mutations are key T-cell targets, but a comprehensive understanding of the nature of a successful antitumor T-cell response is lacking. To investigate the T-cell receptor (TCR) repertoire associated with treatment success versus failure, we used a well-characterized mouse carcinoma that is rejected by CD8 T cells in mice treated with radiotherapy (RT) and anti–CTLA-4 in combination, but not as monotherapy, and comprehensively analyzed tumor-infiltrating lymphocytes (TILs) by high-throughput sequencing of the TCR&Bgr; CDR3 region. The combined treatment increased TIL density and CD8/CD4 ratio. Assessment of the frequency of T-cell clones indicated that anti–CTLA-4 resulted in fewer clones and a more oligoclonal repertoire compared with untreated tumors. In contrast, RT increased the CD8/CD4 ratio and broadened the TCR repertoire, and when used in combination with anti–CTLA-4, these selected T-cell clones proliferated. Hierarchical clustering of CDR3 sequences showed a treatment-specific clustering of TCRs that were shared by different mice. Abundant clonotypes were commonly shared between animals and yet treatment-specific. Analysis of amino-acid sequence similarities revealed a significant increase in the number and richness of dominant CDR3 motifs in tumors treated with RT + anti–CTLA-4 compared with control. The repertoire of TCRs reactive with a single tumor antigen recognized by CD8+ T cells was heterogeneous but highly clonal, irrespective of treatment. Overall, data support a model whereby a diverse TCR repertoire is required to achieve tumor rejection and may underlie the synergy between RT and CTLA-4 blockade. Cancer Immunol Res; 6(2); 139–50. ©2017 AACR.

[1]  T. Chan,et al.  ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis , 2017, Cancer Immunology Research.

[2]  R. Emerson,et al.  Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities , 2016, Proceedings of the National Academy of Sciences.

[3]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[4]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[5]  Jing Ma,et al.  Preferential Use of Public TCR during Autoimmune Encephalomyelitis , 2016, The Journal of Immunology.

[6]  S. Demaria,et al.  In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. , 2015, Vaccine.

[7]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[8]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[9]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[10]  E. Komech,et al.  tcR: an R package for T cell receptor repertoire advanced data analysis , 2015, BMC Bioinformatics.

[11]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[12]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[13]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[14]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[15]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[16]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[17]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[18]  S. Demaria,et al.  Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes , 2014, Journal of Immunotherapy for Cancer.

[19]  N. Friedman,et al.  T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity , 2014, Genome research.

[20]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[21]  Antoni Ribas,et al.  Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[22]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[23]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[24]  R. Emerson,et al.  Using synthetic templates to design an unbiased multiplex PCR assay , 2013, Nature Communications.

[25]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[26]  Peter Schirmacher,et al.  Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue , 2013, Cancer Immunology, Immunotherapy.

[27]  N. Kawashima,et al.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. , 2012, The Journal of clinical investigation.

[28]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[29]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[30]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[31]  Kimberly R. Jordan,et al.  TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines , 2012, Cancer Immunology, Immunotherapy.

[32]  Henrik Schmidt,et al.  A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma , 2011, Journal of Translational Medicine.

[33]  J. Wolchok,et al.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. , 2010, Seminars in oncology.

[34]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[35]  N. Kawashima,et al.  Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade , 2009, Clinical Cancer Research.

[36]  N. Kawashima,et al.  Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1 , 2008, The Journal of Immunology.

[37]  S. Quezada,et al.  Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy , 2008, Immunological reviews.

[38]  B. Neyns,et al.  Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells1 , 2008, The Journal of Immunology.

[39]  Hadley Wickham,et al.  Reshaping Data with the reshape Package , 2007 .

[40]  Robert C. Rose,et al.  Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.

[41]  P. Coulie,et al.  Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen , 2005, The Journal of experimental medicine.

[42]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[44]  T. Lumley,et al.  gplots: Various R Programming Tools for Plotting Data , 2015 .

[45]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[46]  Kimberly R. Jordan,et al.  Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. , 2013, Cancer research.

[47]  Marie-Paule Lefranc,et al.  IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs , 2004, ISMB/ECCB.